Skip to content
Back to Home

Last updated: 16/09/2024

Expand access to bariatric surgery

Double the amount of people living with obesity receiving surgery (from approx 6,500 per year to 13,000 per year)

  • Low impact on obesity

    A percentage estimate of how much the policy would reduce national obesity rates

    • Relative reduction in obesity prevalence: 0.4%
  • Very high evidence quality

    A rating of the strength of evidence, accounting for both reliability and validity of the evidence

    • Reliability and validity rating: 5/5
  • High cost to governments

    Cost to UK and devolved governments over 5 years

    • Costs to governments over 5 years: £250m
    • Benefit to governments per year: £0.2bn

What is the policy?

The policy would increase the number of people that can access weight-loss surgery. Weight-loss surgery, also known as bariatric surgery, makes the stomach smaller. This leads to people feeling full sooner and, therefore, eating less and reducing their calorie consumption. Bariatric surgery is effective for long-term weight loss yet, just 0.2% of eligible individuals undergo bariatric surgery. This is primarily due to insufficient access to bariatric surgery services. This policy seeks to increase the number of eligible individuals undergoing bariatric surgery by increasing funding for bariatric surgery services.

Recent context

Guidelines state that individuals may qualify for bariatric surgery if they have a BMI of 40 kg/m2, or a BMI of 35 kg/m2 or more with a significant obesity-related health problem, such as high blood pressure or type 2 diabetes. Bariatric surgery achieves long-term weight loss, with individuals maintaining a ~17% decrease in body weight after 20 years. Moreover, bariatric surgery leads to improvements in obesity-related disease. However, despite its effectiveness, only a small proportion of those eligible undergo surgery. There are many reasons for this discrepancy including a lack of awareness of the procedure’s effectiveness and safety, prolonged and bureaucratic application processes, and perceptions and stigma related to the surgery. The most salient reason is insufficient funding, leading to a long NHS wait list; it is not currently possible to operate on every individual that meets the criteria.

NHS services and funding are devolved in Wales, but funding is impacted by the Barnett Formula (the formula ensures that any change in English public spending announced for a devolved area, like the NHS, is reflected by a change in the block grants). The All Wales Weight Management Pathway 2021 aligns its qualifying criteria to those of the NICE guidelines for bariatric surgery. The new 2021 All Wales Weight Management Pathway has been designed to address inconsistent implementation of bariatric surgery across the seven Health Boards (which was identified in 2014 by a Senedd Inquiry) by providing a single pathway. 

NHS services and funding are devolved in Scotland, but funding is impacted by the Barnett Formula (the formula ensures that any change in English public spending announced for a devolved area, like the NHS, is reflected by a change in the block grants). In Scotland, the decision to undertake bariatric surgery is jointly made between clinicians and patients, taking account of relevant guidance, Health Board criteria and the patient’s individual circumstances, including their fitness for surgery. NHS services and funding are devolved in Scotland, so any funding for expanding access to bariatric surgery would be agreed and administered by the Scottish Government via NHS Scotland.  

Case studies

Access to bariatric surgery, Sweden

Despite having one of the highest rates of obesity, England lags behind other European nations in bariatric surgery rates. In Sweden, for example, despite the obesity rate being ~12%, bariatric surgery rates are 65 per 100,000 people per year.

Conversely, the UK obesity rate is ~25%, yet bariatric surgery rates are just 9 per 100,000 people per year.

A Swedish prospective, matched-control trial (the Swedish Obese Subjects trial) evaluated the effect of bariatric surgery on weight loss in 2,010 individuals living with obesity compared to 2,037 contemporaneously-matched control individuals receiving ‘usual care’. Mean reductions in body weight for the bariatric surgery group was: 23% (27.8kg) after two years, 17% (20.6kg) after 10 years, 16% (19.4kg) after 15 years, and 18% (21.8kg) after 20 years). In comparison, mean reductions in body weight for the usual care group were: 0% after two years, 1% after 10 years, 1% after 15 years, and 1% after 20 years. In conclusion, increasing access to bariatric surgery in Sweden lowered obesity rates.

Considerations for implementation

Whilst commissioning for bariatric surgery is led by Integrated Care Systems, this level of increase in bariatric surgery would likely require national-level action considering the following:

  • Estates (theatre and clinic space): both clinic and theatre space is in short supply and consequently expanding surgery in one specialty would either be in lieu of other operations or require expanded estates.
  • Workforce: a five-fold expansion in bariatric surgery rates would require significant expansion of the workforce which can perform bariatric surgery. There is a significant lead-in time to train surgeons to be able to perform bariatric surgery.
  • Waiting lists: ambitions of expanding access need to be considered in the context of current long waiting lists. 
  • Tier 3 services: based on current guidelines, patients who receive bariatric surgery should also receive tier 3 service care. Expansion of bariatric surgery therefore requires additional resource tier 3 service care to meet increased demand.
  • Access: patients access bariatric surgery via general practice and consequently GP staff play an important role in identifying eligible patients and referring.

Estimating the population impact

We estimated that this policy would reduce the prevalence of adult UK obesity rates by approximately 0.4%

Estimating the per-person impact

We used findings from the Swedish Obesity Study, reported by Sjöström (2013). This study is a longitudinal, prospective controlled trial to provide information on the effects of bariatric surgery on weight change, disease incidence and mortality. The study followed 2,010 individuals who underwent bariatric surgery (gastric bypass, banding, and vertical banded gastroplasty), as well as 2,037 individuals who did not receive surgery but were matched for demographic variables. Average changes in body weight for people who underwent surgery were -23% (two years), -17% (10 years) and -16% (15 years), compared with 0% (two years), +1% (10 years) and -1% (15 years) for those in the usual care group. For more information about the study and how we identified the best evidence, please see here.

Estimating the population reach

Unlike most other policies, including the treatment policies, this policy applies only to individuals with a BMI of 35 and above (living with a pre-existing condition like hypertension and type 2 diabetes). We did not include individuals with a BMI of 30–34.9 in the analytical model for this policy.  

Changes in the prevalence of people living with obesity

Table 1 shows the percentage reduction of adults moving from a BMI greater than 30 into a healthier BMI category following introduction of this policy (five-year follow up). After five years of policy implementation, 0.4% of adults in England would move from a BMI of greater than 30 to a healthier BMI category.

The low rate of change is explained by the fact that this policy targets individuals with a very high BMI score. Hence, the policy would result in a large number of people moving from a BMI of 35+ to a healthier BMI of 30–34.9, which would result in improved health outcomes, but would not result in living with a BMI of <30 (our outcome of interest).

Adults (England and Wales)Children (England and Wales)Adults (Scotland)Children (Scotland)
0.4%Not applicableIn progressNot applicable
Table 1. Approximate proportion of adults no longer living with obesity (BMI<30) after five years

Cost and benefits

Cost over 5 years

We estimated that this policy would cost the governments approximately £250 million over five years

We commissioned HealthLumen to estimate the cost of the policy to both industry and governments over a five-year period. 

Table 2 below shows a breakdown of costs. The direct costs to the governments are estimated at approximately £250 million. This includes infrastructure costs in the first year for the building of new facilities in the first instance, followed by the average annual cost of conducting surgery on double the current number of patients (i.e., approximately 6,500 to 13,000). Please see cost calculations appendix for more details.

Group affectedCostHorizonDetail
Costs
Government£250m Annual (5 years)Average cost of conducting surgeries (within the NHS and privately). Note that this will include a high cost in year one due to the ‘in-house’ costs of building a new surgery and training surgeons. 
Table 2. Summary of costs

Total annual benefit

We estimated that this policy would have an annual benefit of approximately £0.2 billion

Using analysis conducted by the Tony Blair Institute and Frontier Economics we estimate this policy would result in benefits of approximately £0.2 billion per year. Approximately two-thirds of this saving would benefit individuals (via quality-adjusted life years, and informal social care). The remaining third relates to savings that benefit the state via NHS treatment costs, productivity and formal social care. See our Methods page for more information about the cost breakdowns. 

This figure is a very conservative estimate of the savings as it only includes benefits accrued for individuals who fall under the BMI threshold of 30 after five years. There would be additional cost savings associated with individuals moving from the BMI category of 35+ to the BMI category of 30–34.9, however we did not include this in our model.

Impact on disease incidence

We commissioned HealthLumen to report disease incidence avoided if the policy were implemented. These estimates do not represent the total health benefits. The specific diseases selected are those where there is good evidence that living with obesity is associated with the development of the disease. 

Based on our analysis and analysis conducted by HealthLumen, there is no evidence that this policy would impact disease incidence avoided after five years.


Behind the averages: impact on inequalities

Those meeting criteria for bariatric surgery are typically older, are from racial or ethnic minority backgrounds, are more economically disadvantaged and have a lower educational attainment. However, this cohort of individuals may have the greatest barriers to accessing bariatric surgery. Most evidence for this effect comes from the USA. 

A retrospective analysis of individuals undergoing bariatric surgery at a UK-regional centre found that older and younger adults, men and people from ethnic minority groups were underrepresented. In part, differences in access may be related to the marked regional variation in eligibility criteria for bariatric surgery. Further work is needed to identify socioeconomic disparities in access to bariatric surgery in the UK.

Rating the strength of evidence

We asked experts working in the fields of obesity, food, and health research to rate the strength of the evidence base for each policy, taking into account both reliability (size and consistency) and validity (quality and content) of the evidence. Policies were rated on a Likert scale of 1–5 (none, limited, medium, strong, and very strong evidence base). The Blueprint Expert Advisory Group rated this policy as having a Very Strong evidence base.

Large scale roll-out of pharmacological interventions

Extend access to pharmacotherapy so that approximately 3 million people (BMI≥30) receive Semaglutide each year